An optimal dose ‐fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early‐stage non‐small lung cancer
1.In peripheral tumors shorter interval between fractions does not increase toxicity.
2.Treatment on consecutive days is recommended.
3.In peripheral tumors up to 5 cm radiosurgery is recommended. In tumors abutting chest wall – 5 × 11 Gy
4.In central tumors>1 cm from main bronchi 5 × 10 Gy, in ultracentral tumors 8 × 7.5 Gy. In gross endobronchial infiltration the schedule of 8 × 7 Gy should be avoided. In coexistence of risk factors for inducing hemoptysis such patients should be treated with extreme caution.
5.In ultracentral tumors short schedules of<3 fractions should be avoided.
6.Re...
Source: Thoracic Cancer - September 11, 2023 Category: Cancer & Oncology Authors: Izabela Zar ębska,
Maciej Harat Tags: REVIEW Source Type: research
miR ‐1301‐3p promotes invasion and migration and EMT progression in esophageal cancer by downregulating NBL1 expression
ConclusionMiR-1301-3p is a potential biomarker for predicting the prognosis of ESCA patients. It may promote ESCA invasion, migration and EMT progression by regulating NBL1 expression. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 8, 2023 Category: Cancer & Oncology Authors: Jianting Du,
Shuliang Zhang,
Xiaodan Zhang,
Zhang Yang,
Songtao Xue,
Guobing Xu,
Bin Zheng,
Chun Chen Tags: ORIGINAL ARTICLE Source Type: research
CircPKM2 aggravates the progression of non ‐small cell lung cancer by regulating MTDH via miR‐1298‐5p
ConclusionOur findings demonstrated that circPKM2 mediated NSCLC progression via regulating miR-1298-5p/MTDH axis, providing a novel therapeutic target for NSCLC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 7, 2023 Category: Cancer & Oncology Authors: Shuhua Gao,
Tingting Gao,
Li Feng,
Haixia Li,
Guogang Dong,
Shan Yang Tags: ORIGINAL ARTICLE Source Type: research
Artificial intelligence ‐powered spatial analysis of tumor‐infiltrating lymphocytes as a biomarker in locally advanced unresectable thymic epithelial neoplasm: A single‐center, retrospective, longitudinal cohort study
ConclusionsNondesert IP in initial biopsy was associated with a better response to neoadjuvant therapy. Increased infiltration of both iTIL and sTIL in surgical specimens were associated with longer OS in patients with TET who underwent resection followed by neoadjuvant therapy. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 7, 2023 Category: Cancer & Oncology Authors: Dong Hyun Kim,
Yoojoo Lim,
Sukjun Kim,
Chan ‐Young Ock,
Jeonghwan Youk,
Miso Kim,
Tae Min Kim,
Dong‐Wan Kim,
Hak Jae Kim,
Jiwon Koh,
Kyeong Cheon Jung,
Kwon Joong Na,
Chang Hyun Kang,
Bhumsuk Keam Tags: ORIGINAL ARTICLE Source Type: research
Effectiveness and safety of human type 5 recombinant adenovirus (H101) in malignant tumor with malignant pleural effusion and ascites: A multicenter, observational, real ‐world study
ConclusionEncouraging clinical benefits and manageable toxicity of H101 against MPE/MA were preliminarily observed in the real-world clinical setting, indicating that the H101-containing regimen is reliable, safe, and feasible, providing a novel and effective option for the treatment of this disease. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 7, 2023 Category: Cancer & Oncology Authors: Baocheng Wang,
Chen Zhong,
Zijun Liao,
Haitao Wang,
Xiuyu Cai,
Yanbing Zhang,
Jun Wang,
Tianxiao Wang,
Hongtao Yao Tags: ORIGINAL ARTICLE Source Type: research
The role of microbiota in esophageal squamous cell carcinoma: A review of the literature
In conclusion, esophageal dysbiosis is associated with ESCC progression and chemoresistance. Screening the oral and esophageal microbiota is a potential diagnostic tool for predicting ESCC development or drug-resistance. Repairing esophageal dysbiosis is a novel treatment for ESCC. Clinical trials with probiotics in addition to current chemotherapy are warranted to study the therapeutic effects. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 7, 2023 Category: Cancer & Oncology Authors: Hsueh ‐Chien Chiang,
Michael Hughes,
Wei‐Lun Chang Tags: REVIEW Source Type: research
Phase II study of IRInotecan treatment after COmbined chemo ‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study
This study demonstrates and re-evaluates the clinical benefits of irinotecan after combined treatment with anti-PD-L1 and platinum-etoposide for patients with ES-SCLC.Registration detailsThis study was registered in the Japan Registry of Clinical Trials (no. jRCT s071210090) on November 4, 2021. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 7, 2023 Category: Cancer & Oncology Authors: Hiromi Tomono,
Hirokazu Taniguchi,
Minoru Fukuda,
Takaya Ikeda,
Seiji Nagashima,
Kazumasa Akagi,
Sawana Ono,
Yasuhiro Umeyama,
Midori Shimada,
Hiroshi Gyotoku,
Shinnosuke Takemoto,
Yasushi Hisamatsu,
Ryotaro Morinaga,
Ryuta Tagawa,
Ryosuke O Tags: STUDY PROTOCOL Source Type: research
Adiponectin ‐expressing Treg‐containing T cell fraction inhibits tumor growth in orthotopically implanted triple‐negative breast cancer
ConclusionsBased on our findings, the T cell fraction comprising adiponectin-expressing Tregs, represents a potential candidate for adoptive cell therapy against TNBC. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 7, 2023 Category: Cancer & Oncology Authors: Wakana Chikaishi,
Toshiya Higashi,
Hirokatsu Hayashi,
Yuki Hanamatsu,
Manabu Futamura,
Nobuhisa Matsuhashi,
Chiemi Saigo,
Tamotsu Takeuchi Tags: ORIGINAL ARTICLE Source Type: research
Issue Information
(Source: Thoracic Cancer)
Source: Thoracic Cancer - September 6, 2023 Category: Cancer & Oncology Tags: ISSUE INFORMATION Source Type: research
Pretreatment eosinophil counts as a predictive biomarker in non ‐small cell lung cancer patients treated with immune checkpoint inhibitors
ConclusionOS was significantly longer in ICI-treated NSCLC patients with a pretreatment eosinophil count of 100 ≤ Eo<500 than in the other patients and, thus, has potential as a new predictive biomarker. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 6, 2023 Category: Cancer & Oncology Authors: Eiji Takeuchi,
Kensuke Kondo,
Yoshio Okano,
Seiya Ichihara,
Michihiro Kunishige,
Naoki Kadota,
Hisanori Machida,
Nobuo Hatakeyama,
Keishi Naruse,
Hirokazu Ogino,
Hiroshi Nokihara,
Tsutomu Shinohara,
Yasuhiko Nishioka Tags: ORIGINAL ARTICLE Source Type: research
N6 ‐methyladenosine‐modified circFUT8 competitively interacts with YTHDF2 and miR‐186‐5p to stabilize FUT8 mRNA to promote malignant progression in lung adenocarcinoma
ConclusionsThese findings identified a novel m6A-modified circFUT8 recognized and destabilized by YTHDF2, which competitively interacted with YTHDF2 and miR-186-5p to stabilize FUT8 mRNA to promote malignant progression in LUAD. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 6, 2023 Category: Cancer & Oncology Authors: Gaochao Dong,
Yingkuan Liang,
Bing Chen,
Te Zhang,
Hui Wang,
Yuzhong Chen,
Yijian Zhang,
Feng Jiang,
Yaping Wang Tags: ORIGINAL ARTICLE Source Type: research
Lymph node metastasis and its risk factors in T1 lung adenocarcinoma
ConclusionsIn patients with clinical stage T1 lung adenocarcinoma, the risk of lymph node metastasis is higher for tumors located deep within the lung tissue with solid components, invasive preoperative imaging features, and larger diameters. For N2 skip lymph node metastasis, the micropapillary pathological subtype represents a significant high-risk factor. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 5, 2023 Category: Cancer & Oncology Authors: Wenhao Zhang,
Guang Mu,
Jingjing Huang,
Chengyu Bian,
Hongchang Wang,
Yan Gu,
Yang Xia,
Liang Chen,
Mei Yuan,
Jun Wang Tags: ORIGINAL ARTICLE Source Type: research
Delayed esophageal anastomotic complication and ramucirumab therapy: A case report
In conclusion, this is the only known report of delayed esophageal anastomotic complication associated with ramuciru mab. VEGF inhibitor therapies such as bevacizumab have been associated with late (greater than 3 months postoperative) colorectal anastomotic complications including fistulas and leaks. Risk factors that have been associated are perioperative radiotherapy and history of early postoperative leak. The se findings raise concern whether VEGF inhibitor therapy should be used in post-esophagectomy patients with recurrence if these rare but catastrophic events are likely to be terminal. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 5, 2023 Category: Cancer & Oncology Authors: Robert H. Roth,
Madison J. Malfitano,
Matthew Reilley,
Linda W. Martin Tags: CASE REPORT Source Type: research
Efficacy and safety of cyclin ‐dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A real‐world experience
ConclusionCDK4/6i administered in a real-world setting exhibits a similar survival benefit with the clinical trials. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 5, 2023 Category: Cancer & Oncology Authors: Tzu ‐Rong Peng,
Jia‐Hui Chen,
Ta‐Wei Wu Tags: ORIGINAL ARTICLE Source Type: research
Lung adenocarcinoma with micropapillary and solid patterns: Recurrence rate and trends
ConclusionsEarly-stage lung adenocarcinoma with MP or SP frequently has postoperative recurrence. Prevention of distant metastases is important in these patients to improve prognosis, and aggressive postoperative chemotherapy may be considered. (Source: Thoracic Cancer)
Source: Thoracic Cancer - September 3, 2023 Category: Cancer & Oncology Authors: Naoki Takeno,
Shintaro Tarumi,
Masahiro Abe,
Yasuhiro Suzuki,
Ichiro Kinoshita,
Tatsuya Kato Tags: ORIGINAL ARTICLE Source Type: research
